Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Prelude Therapeutics Inc (PRLD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Enrollment of Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer is underway; initial proof of concept data anticipated
How this was made
The 30-second read
Why it matters
The report provides fresh material for investors evaluating early‑stage oncology pipelines, with upcoming data points that could drive volatility.
Market read
Primary disclosure of earnings and pipeline milestones for a micro‑cap biotech, offering new information for short‑term trading considerations.
What to watch
Potential dilution from future financing rounds and reliance on partnership with Lilly for combination studies.
Prelude Therapeutics reports Q3 2026 net loss of $(12,544) thousand, or $(0.12) per share, down from $(19,725) thousand, or $(0.26) per share, a year earlier; cash runway into Q2 2028
Operating costs fell sharply and the net loss narrowed, but revenue declined to $5,647 thousand from $6,500 thousand, current deferred revenue fell to $19,601 thousand from $33,734 thousand at December 31, 2025, and the filing gives cash runway only into the second quarter of 2028 against $142.7 million in cash, cash equivalents, restricted cash and marketable securities.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Revenue, three months ended September 30, 2026GAAP | $5.65M | – | – |
| Research and development expense, three months ended September 30, 2026GAAP | $14.8M | – | – |
| General and administrative expense, three months ended September 30, 2026GAAP | $5.1M | – | – |
| Total operating expenses, three months ended September 30, 2026GAAP | $19.91M | – | – |
| Loss from operations, three months ended September 30, 2026GAAP | −$14.27M | – | – |
| Other income, net, three months ended September 30, 2026GAAP | $1.72M | – | – |
| Net loss, three months ended September 30, 2026GAAP | −$12.54M | – | – |
| Net loss per share of common stock, basic and diluted, three months ended September 30, 2026GAAP | $(0.12) per share | – | – |
| Comprehensive loss, three months ended September 30, 2026GAAP | −$12.85M | – | – |
| Non-cash stock-based compensation in R&D expense, three months ended September 30, 2026GAAP | $900K | – | – |
| Non-cash stock-based compensation in G&A expense, three months ended September 30, 2026GAAP | $1.1M | – | – |
| Non-cash share-based payment expense included in net loss, three months ended September 30, 2026GAAP | $2M | – | – |
| Cash, cash equivalents, restricted cash and marketable securities, as of September 30, 2026other | $142.7M | – | – |
| Cash and cash equivalents, balance sheet as of September 30, 2026GAAP | $23.41M | – | – |
| Marketable securities, balance sheet as of September 30, 2026GAAP | $116.6M | – | – |
| Deferred revenue, current, balance sheet as of September 30, 2026GAAP | $19.60M | – | – |
| Total assets as of September 30, 2026GAAP | $175.5M | – | – |
| Total liabilities as of September 30, 2026GAAP | $51.35M | – | – |
| Total stockholders' equity as of September 30, 2026GAAP | $124.1M | – | – |
Capital returns
- No share repurchases or dividends are reported in the filing.
- Voting common stock issued and outstanding rose from 48,225,493 shares at December 31, 2025 to 65,297,977 shares at September 30, 2026, and additional paid-in capital rose from $751,684 thousand to $844,572 thousand over the same period. The filing does not describe the transactions behind these changes.
What drove it
- The company attributes the decrease in R&D expense primarily to lower expense for its SMARCA2 clinical trials, which it paused in 2025, and to lower employee-related expenses following a workforce reduction in the second half of 2025. Non-cash stock-based compensation in R&D also decreased.
- The company attributes the decrease in G&A expense primarily to lower professional fees and employee-related expenses.
- Other income, net rose to $1,721 thousand from $693 thousand. The filing does not state a cause for this change.
- The filing does not explain the decline in revenue to $5,647 thousand from $6,500 thousand.
Concerns
- Revenue fell year over year to $5,647 thousand from $6,500 thousand, and the filing gives no explanation for the decline.
- Current deferred revenue fell to $19,601 thousand from $33,734 thousand at December 31, 2025.
- The company's stated cash runway extends only into the second quarter of 2028, with $142.7 million in cash, cash equivalents, restricted cash and marketable securities as of September 30, 2026.
- The exclusive option agreement with Incyte for the JAK2V617F inhibitor program is set to expire in February 2027, with potential for a 3-month extension.
- Initial proof of concept data for PRT13722 is anticipated only in the second half of 2027, and the filing contains no timing for data from the PRT12396 or mCALR DAC programs.
What to watch
- Whether the Incyte option on the JAK2V617F inhibitor program (PRT12396) is exercised, extended or allowed to expire in February 2027, with potential for a 3-month extension.
- Initial proof of concept data from the Phase 1 study of PRT13722, anticipated in the second half of 2027.
- Presentations at the ASH 2026 meeting (December 12-15, 2026) for PRT12396 and the mCALR DAC candidate, and at SABCS 2026 (December 8-11, 2026) for PRT13722.
- The Lilly clinical trial collaboration and supply agreement signed in October 2026 for PRT13722 combinations with abemaciclib and imlunestrant.
- Revenue and deferred revenue trends in the next quarters, given the year-over-year decline and the fall in current deferred revenue.
- Progress toward or changes to the stated cash runway into the second quarter of 2028.
Balance sheet and cash flow
- Cash, cash equivalents, restricted cash and marketable securities were $142.7 million as of September 30, 2026. The company anticipates this balance will fund operations into the second quarter of 2028.
- Balance sheet comparison with December 31, 2025: cash and cash equivalents $23,412 thousand versus $35,256 thousand; marketable securities $116,589 thousand versus $67,958 thousand; restricted cash $2,725 thousand versus $3,235 thousand; total current assets $142,427 thousand versus $105,692 thousand; total assets $175,485 thousand versus $141,315 thousand.
- Deferred revenue, current, fell to $19,601 thousand from $33,734 thousand at December 31, 2025. Deferred revenue, net of current portion, was reported as "-" at September 30, 2026 versus $1,798 thousand at December 31, 2025.
- Total liabilities were $51,349 thousand versus $72,678 thousand at December 31, 2025. Total stockholders' equity rose to $124,136 thousand from $68,637 thousand.
- Accumulated deficit was $(719,911) thousand at September 30, 2026 versus $(683,061) thousand at December 31, 2025.
- The filing contains no cash flow statement, so operating cash flow and free cash flow are not reported.
Analysis
Prelude reported a third-quarter 2026 net loss of $(12,544) thousand, or $(0.12) per share, compared with $(19,725) thousand, or $(0.26) per share, in the prior-year quarter. The improvement came from operating expenses: total operating expenses were $19,912 thousand against $26,918 thousand, with R&D expense at $14.8 million against $21.7 million and G&A expense at $5.1 million against $5.2 million. The company attributes the R&D decline primarily to lower SMARCA2 clinical trial expense, which it paused in 2025, and to a workforce reduction in the second half of 2025. Other income, net was $1,721 thousand, up from $693 thousand, and the filing does not explain this change.
Revenue was $5,647 thousand, down from $6,500 thousand a year earlier. The filing does not give a reason for the decline. The balance sheet shows current deferred revenue at $19,601 thousand, down from $33,734 thousand at December 31, 2025, and non-current deferred revenue at zero, down from $1,798 thousand. Taken together with the revenue decline, this points to lower recognition of previously collected collaboration-type payments, but the filing itself does not state that cause, so the reader should weigh these two figures side by side.
On the balance sheet, cash, cash equivalents, restricted cash and marketable securities totaled $142.7 million at September 30, 2026. Marketable securities rose to $116,589 thousand from $67,958 thousand while cash and cash equivalents fell to $23,412 thousand from $35,256 thousand. Total stockholders' equity increased to $124,136 thousand from $68,637 thousand, and voting common shares outstanding rose from 48,225,493 to 65,297,977 over the nine months, but the filing does not describe the transactions that produced these changes. The company says the existing balance funds operations into the second quarter of 2028. The filing provides no cash flow statement, so operating and free cash flow cannot be read from this document.
Pipeline updates dominate the release. PRT13722, a KAT6A degrader, began Phase 1 enrollment in Q4 2026, with initial proof of concept data expected in the second half of 2027. The company entered a clinical trial collaboration and supply agreement with Lilly in October 2026 to test PRT13722 with abemaciclib and imlunestrant. PRT12396, a JAK2V617F inhibitor, is enrolling Phase 1 patients, but its exclusive option agreement with Incyte expires in February 2027, with a possible 3-month extension. The mCALR DAC candidate has preclinical data accepted for ASH 2026. None of these programs has a dated efficacy readout in this filing that falls before the 2027 window.
The filing provides no guidance figures, so there is no outlook to compare against. The read therefore rests on the reported quarter: lower spending and a smaller loss, offset by lower revenue, a sharp fall in current deferred revenue, and a runway that the company places into the second quarter of 2028. The most useful next data points are the Incyte option outcome, the timing of PRT13722 data, and the next quarter's revenue and deferred revenue balances.
Management, verbatim
The first three quarters of 2026 have been a period of strong execution for Prelude
Kris Vaddi, Ph.D., Chief Executive Officer
With multiple clinical readouts expected over the next 12 to 18 months, we are well positioned to enter 2027 with the momentum to drive future growth of Prelude.
Kris Vaddi, Ph.D., Chief Executive Officer
Not in the filing
stated, not guessed- Prior quarter (Q2 2026) figures for revenue, operating expenses, net loss and EPS
- Year-over-year and sequential percentage changes for revenue, R&D, G&A, operating expenses, net loss and EPS
- Company guidance for 2026 or 2027 (no guidance figures are printed in the filing)
- Nine-month year-to-date results and comparisons
- Cash flow statement, operating cash flow, investing cash flow, financing cash flow and free cash flow
- Explanation of the decline in revenue and of the decline in current deferred revenue
- Description of the transactions that increased voting common shares outstanding and additional paid-in capital
- Revenue breakdown by source or collaboration partner
- Previous outlook for comparison (no prior release outlook was provided)
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
The 8‑K serves as Prelude Therapeutics' quarterly financial and R&D update, highlighting cash position, FDA clearance, and collaborations.
Ticker impact
Prelude Therapeutics filed an 8‑K reporting Q3 2026 results and updates on its Phase 1 KAT6A degrader and JAK2V617F programs, including new FDA clearance and a collaboration with Eli Lilly.
potential modest upside as investors price in upcoming proof‑of‑concept data, but limited immediate catalyst.
New FDA clearance and partnership are material for a biotech, yet the company remains early‑stage with no near‑term revenue, so market reaction may be muted.
Market effects
Adds to momentum in the precision‑oncology sector as multiple early‑stage programs advance toward data readouts.
Limited to US biotech investors; no broader regional effect.
Minor, confined to specialty pharma and biotech niche.
Counterpoint
If upcoming trial data disappoint, the stock could face sharp downside despite cash runway.
Key entities
- companyPrelude Therapeutics Inc.
Clinical‑stage precision oncology company.
- partnerEli Lilly and Company
Provides abemaciclib and imlunestrant for combination trials.
